MannKind (MNKD)
(Delayed Data from NSDQ)
$4.80 USD
-0.24 (-4.76%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $4.79 -0.01 (-0.21%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth D Momentum B VGM
Brokerage Reports
MannKind Corporation [MNKD]
Reports for Purchase
Showing records 221 - 228 ( 228 total )
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
A good day for MannKind: done with FDA meeting, successful Type 1 diabetes Phase III trial
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: MannKind Corporation
Industry: Medical - Biomedical and Genetics
It''s a CRL but no need for new studies, no safety issues raised: bear story loses a lot of its punch.
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S